On Tuesday, MC2 Therapeutics and its partner Almirall announced that they had completed the EU decentralized procedure for the psoriasis treatment Wynzora, which is the last step before individual the health authorities in individual European countries can start issuing marketing authorizations.
For MC2, which developed Wynzora, the fact that the drug is on the brink of being launched in the EU and the US is the culmination of many years of work. It was approved in the US last year.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.